Myriad Genetics to Host Fourth Quarter and Full Year 2025 Earnings Conference Call on February 23, 2026

Myriad Genetics will discuss 2025 earnings on Feb. 23, 2026, with webcasts available post-call.

Quiver AI Summary

Myriad Genetics, Inc. will host its fourth quarter and full year 2025 earnings conference call on February 23, 2026, at 4:30 pm ET, with financial results released the same day after market close. The call will provide insights into the company’s performance, and interested parties can access the live webcast on Myriad’s Investor Relations website or register for a telephone participation. Additionally, key executives will participate in several upcoming investor healthcare conferences. Myriad Genetics is focused on advancing health through genetic testing and precision medicine, aimed at improving patient care and reducing healthcare costs. For further information, contact details for investor and media inquiries are provided.

Potential Positives

Myriad Genetics is hosting its fourth quarter and full year 2025 earnings conference call, providing transparency about its financial performance, which can build investor confidence.
The participation of Myriad’s CEO and CFO in multiple upcoming investor healthcare conferences indicates the company's commitment to engaging with investors and stakeholders.
The focus on genetic testing and precision medicine positions Myriad Genetics in a growing market, highlighting its role in advancing healthcare and potentially increasing demand for its services.

Potential Negatives

The press release does not include any specific financial results or projections, which may raise concerns about the company's performance for Q4 and the full year 2025.
The lack of detailed information regarding the financial overview and business update may lead to investor uncertainty prior to the earnings call.
Not providing key financial metrics ahead of the earnings call could negatively impact investor confidence in the company's transparency and communication practices.

FAQ

What date is Myriad Genetics' 2025 earnings conference call?

Myriad Genetics' 2025 earnings conference call is scheduled for February 23, 2026, at 4:30 pm ET.

How can I access the earnings call webcast?

The earnings call webcast can be accessed on Myriad Genetics' Investor Relations website at investor.myriad.com.

Who will present at the upcoming investor conferences?

Sam Raha, President and CEO, and Ben Wheeler, CFO, will present at the upcoming investor healthcare conferences.

When will Myriad's fourth quarter earnings be released?

Myriad's fourth quarter earnings will be released on February 23, 2026, after the market closes.

How can I contact Myriad Genetics for investor inquiries?

You can contact Myriad Genetics for investor inquiries at [email protected] or call Matt Scalo at (801) 584-3532.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$MYGN Revenue

$MYGN had revenues of $205.7M in Q3 2025. This is a decrease of -3.56% from the same period in the prior year.

You can track MYGN financials on Quiver Quantitative's MYGN stock page.

$MYGN Hedge Fund Activity

We have seen 119 institutional investors add shares of $MYGN stock to their portfolio, and 120 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

KENT LAKE PR LLC removed 1,250,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $9,037,500
PORTOLAN CAPITAL MANAGEMENT, LLC removed 1,163,400 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $8,411,382
CITADEL ADVISORS LLC removed 1,138,871 shares (-66.6%) from their portfolio in Q3 2025, for an estimated $8,234,037
STATE STREET CORP added 990,075 shares (+19.9%) to their portfolio in Q4 2025, for an estimated $6,088,961
ALGERT GLOBAL LLC added 913,065 shares (+inf%) to their portfolio in Q3 2025, for an estimated $6,601,459
QUBE RESEARCH & TECHNOLOGIES LTD removed 865,081 shares (-42.2%) from their portfolio in Q3 2025, for an estimated $6,254,535
ANSON FUNDS MANAGEMENT LP removed 841,938 shares (-62.5%) from their portfolio in Q3 2025, for an estimated $6,087,211

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$MYGN Analyst Ratings

Wall Street analysts have issued reports on $MYGN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Piper Sandler issued a "Overweight" rating on 11/11/2025

To track analyst ratings and price targets for $MYGN, check out Quiver Quantitative's $MYGN forecast page.

$MYGN Price Targets

Multiple analysts have issued price targets for $MYGN recently. We have seen 4 analysts offer price targets for $MYGN in the last 6 months, with a median target of $8.25.

Here are some recent targets:

Dave Weiner from Piper Sandler set a target price of $8.5 on 11/11/2025
Brandon Couillard from Wells Fargo set a target price of $6.5 on 11/05/2025
Lu Li from UBS set a target price of $8.0 on 11/04/2025
Dan Brennan from TD Cowen set a target price of $9.0 on 11/04/2025

Full Release

SALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular testing and precision medicine, will hold its fourth quarter and full year 2025 earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the fourth quarter and full year 2025.

A live webcast of the earnings conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com . To participate in the live conference call via telephone, please register here . Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at investor.myriad.com following the call.

Upcoming Investor Conferences
Sam Raha, President and CEO, and Ben Wheeler, Chief Financial Officer, will participate in the following investor healthcare conferences:

The TD Cowen 46th Annual Health Care Conference in a fireside chat at 3:10 pm ET on Tuesday, March 3, 2026.
The Leerink Partners Global Healthcare Conference in a fireside chat at 1:40 pm ET on Tuesday, March 10, 2026.
The Barclays 28 ^th Annual Global Healthcare conference in 1-on-1 meetings on Wednesday, March 11, 2026.

Live and archived webcasts of presentations at TD Cowen and Leerink Partners can be viewed at investor.myriad.com .

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com .

Investor Contact
Matt Scalo
(801) 584-3532
[email protected]

Media Contact
Kate Schraml
(385) 318-3718
[email protected]